Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ocimum Biosolutions, an integrated genomics company, has received new US patent that describes elucidation of the global changes in gene expression and identification of toxicity markers in tissues or cells exposed to a known renal toxin.
Subscribe to our email newsletter
The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.
Anu Acharya, CEO of Ocimum Biosolutions, said: “We have consistently been in the forefront of genomics innovation over many years and this patent reiterates our strong commitment to continue as a leader in this space.”